Singapore: Italian firm, Abiogen Pharma, focused on bone metabolism, has partnered with Hong Kong based Lee's Pharmaceutical for license, distribution and supply for marketing of Thorens Cholecalciferol (or vitamin D3) throughout mainland China, Hong Kong, Macau and Taiwan.

Abiogen has granted Lee's an exclusive license and right for registering, importing, marketing, distributing and selling the Cholecalciferol finished products (oral drops, oral solution and solution for injection), for the prevention and treatment of vitamin D deficiency.

Dr Massimo Di Martino, president and CEO, Abiogen said, "I am very pleased to extend our strategic collaboration to valorize Lee's capacities in Hong Kong, mainland China and other countries. Deficiency of vitamin D is a Global Silent Epidemic. We have the means to address this threat and we should start in the most populated countries of the world."

"We are excited to expand our partnership with Abiogen in this important area of bone metabolism," said Dr Benjamin Li, CEO, Lee's. "Vitamin D deficiency is a growing problem, especially in patients on dialysis. The availability of Cholecalciferol will certainly strengthen Lee's' presence in the dialysis area where the Group's leading product has been helping the improvement of quality of life of dialysis patient."